HOME

SMOKE FOR FREE e-cigarette

TESTIMONIALS

FAQ   E-CIGARETTE

e-cigarette TROUBLE SHOOTING

e-cigarette supplies and accessories

e-cigarette Guarantee

Contact


E-Cigarette Articles and Blogs

 
 

Products

 
Model 501 e-cigarette Kit
Model 701 electronic cigarette Kit
Model  84-c electronic cigarette Kit
Model #702  PCC e-cigarette  Kit
Model # 801 electronic cigarette
 

 

 

 

IMPORTANT: If you or someone you know has benefited from Electronic Cigarettes, please Sign the Electronic Cigarette Petition to the FDA.

Recent Blog Posts

          From Luck-e-Strike

          What are the Economic Costs of Smoking

          What We Already Know About Smoking

 

FROM LUCK-E-STRIKE        

Today there is some controversy regarding E-Cigarettes. It seams the FDA is being pushed to regulate  E-Cigarettes. Here at Luck e Strike we market solely to existing tobacco smokers who want a cheaper and healthier alternative to tobacco smoking. I do not believe the FDA or any other non-smoking advocate group can successfully argue that  E-Cigarettes are more harmful than traditional tobacco cigarettes but the FDA has done a short study and found traces of some carcinogen chemicals. All far lower than what would be considered  harmful amounts but they have to start somewhere to justify a more longer term study, which they probably will never do. Their study is so flawed below you will be-able to read rebuttals to their ridicules claims

So now were back to the private sector performing their own studies which will generally take some years and a couple hundred thousand case study people. Now they can submit their findings to the FDA which will look at their studies and determine if they carry any merit. Then if the FDA feels that the private sector studies are OK they will then want to perform their own case studies to see if they will come up with the same results and then vote on whether to pass for consumer consumption or not. This whole process an take up to 5 yrs.

    We feel they are more driven by big tobacco companies and lost tax revenue than anything else. What they are failing to consider is the overall health benefits to our current failing health care system. They want to supply health care to all our citizens but can not figure out how to pay for it. Well FDA here is a novel thought why not reduce some of the most costly procedures our hospitals are performing everyday. Yes we are talking about all the cancer, respiratory and coronary artery problems that regular tobacco cigarettes contribute to. These procedures are so costly that today we have hospitals that specialize in one or the other.

 

 

What are the economic costs of smoking?

 

We are making great progress in reducing the number of Americans who smoke and the number of Americans who die prematurely due to tobacco use. However, the financial burden on individuals and society as a result of smoking remain immense.

During 1997 through 2001, smoking cost the US approximately $167 billion annually. This figure includes about $92 billion from loss of productivity due to premature death and $75 billion in smoking-related health care costs. Utah incurs about $273 million each year in direct medical expenses and $257 million in lost productivity.

 

Nationally, one in five of all deaths are related to tobacco use. It kills more than 430,000 people every year--more than AIDS, alcohol, drugs abuse, automobile accidents, murders, suicides, and fires combined. Five million years of potential life is lost every year due to premature death caused by tobacco use, medical costs total more than $50 billion annually, and indirect cost another $50 billion.

Of the 4,000 or more different chemicals present in cigarette smoke, 60 are known to cause cancer and others to cause cellular genetic mutations that can lead to cancer.

(Source Link) CDC

 

 

 

What We Already Know About Cigarette smoking

The World Health Organization

 

WHO) has named tobacco one of the greatest public health threats of the twenty-first century. As of 1999, more than one billion people worldwide smoke, and 3.5 million people are expected to die from causes directly related to tobacco use. This death rate is expected to rise to 10 million by the year 2030. Seventy percent of these deaths will occur in developing countries where the proportion of smokers is growing, particularly among women. Calling tobacco "a global threat," WHO says these figures do not include the enormous physical, emotional, and economic costs associated with disease and disability caused by tobacco use.

Nationally, one in five of all deaths are related to tobacco use. It kills more than 430,000 people every year--more than AIDS, alcohol, drugs abuse, automobile accidents, murders, suicides, and fires combined. Five million years of potential life is lost every year due to premature death caused by tobacco use, medical costs total more than $50 billion annually, and indirect cost another $50 billion.

Of the 4,000 or more different chemicals present in cigarette smoke, 60 are known to cause cancer and others to cause cellular genetic mutations that can lead to cancer. Cigarette smoke contains nicotine--a highly addictive chemical--tars, nitrosamines, and polycyclic hydrocarbons, all of which are carcinogenic. It also contains carbon monoxide which, when inhaled, interferes with transportation and utilization of oxygen throughout the body.

Scientific evidence has proven that smoking can cause cancer of the lung, larynx, esophagus, mouth, and bladder; cardiovascular disease; chronic lung ailments; coronary heart disease; and stroke. It also prohibits the healing of peptic ulcers, in addition to promoting recurrence of the condition. Smokeless tobacco has equally deadly consequences. When cigarette smoke is inhaled, the large surface area of the lung tissues and alveoli quickly absorb the chemical components and nicotine. Within one minute of inhaling, the chemicals in the smoke are distributed by the bloodstream to the brain, heart, kidneys, liver, lungs, gastrointestinal tract, muscle, and fat tissue. In pregnant women, cigarette smoke crosses the placenta and may effect fetal growth.

Cardiovascular disease, or diseases of the blood vessels and heart, includes stroke, heart attack, peripheral vascular disease, and aortic aneurysm. In 1990 in the United States, one fifth of all deaths due to cardiovascular disease were linked to smoking. Specifically, 179,820 deaths from general cardiovascular disease, 134,235 deaths from heart disease, and 23,281 deaths from cerebrovascular disease (stroke) were directly linked to smoking. In addition, researchers have noted a strong dose-response relationship between the duration and extent of smoking and the death rate from heart disease in men under 65.The more one smokes, the more one is likely to develop heart disease. Researchers have also seen a similar trend in women. Calling tobacco "a global threat," WHO says these figures do not include the enormous physical, emotional, and economic costs associated with disease and disability caused by tobacco use.

Nationally, one in five of all deaths are related to tobacco use. It kills more than 430,000 people every year--more than AIDS, alcohol, drugs abuse, automobile accidents, murders, suicides, and fires combined. Five million years of potential life is lost every year due to premature death caused by tobacco use, medical costs total more than $50 billion annually, and indirect cost another $50 billion. Smoking causes 85% of all lung cancers, and 14% of all cancers--among them cancers of the mouth, pharynx (throat), larynx (voice-box), esophagus, stomach, pancreas, cervix, kidney, ureter, and bladder. More than 171,500 new diagnoses were expected in 1998. Other environmental factors add to the carcinogenic qualities of tobacco. For example, alcohol consumption combined with smoking accounts for three-quarters of all oral and pharyngeal cancers. Also, persons predisposed genetically to certain cancers may develop cancer more quickly if they smoke. Only 14% of lung cancer patients survive five years after diagnosis.

Smoking is the leading cause of lung disease in the United States. Among the direct causes of death are pneumonia, influenza, bronchitis, emphysema, and chronic airway obstruction. Smoking increases mucus production in the airways and deadens the respiratory cilia, the tiny hairs that sweep debris out from the lungs. Without the action of the cilia, bacteria and inhaled particles from cigarette smoke are free to damage the lungs.

In the smaller airways of the lungs--the tiny bronchioles that branch off from the larger bronchi--chronic inflammation is present in smokers which causes airways to constrict causing cough, mucus production, and shortness of breath. Eventually, this inflammation can lead to chronic obstructive pulmonary disease (COPD), a condition in which oxygen absorption by the lungs is greatly reduced, severely limiting the amount of oxygen transported to body tissues.

For the 40 years prior to 1987, breast cancer was the leading cause of cancer deaths among women in the United

Smoking leads to cardiovascular disease in a number of ways. Smoking damages the inside of the blood vessels, initiating changes that lead to atherosclerosis, a disease characterized by blood vessel blockage.  In 1987, lung cancer took the lead. As well as increased risk of cancer and cardiovascular disease, women smokers are at increased risk of osteoporosis (a disease in which bones become brittle and vulnerable to breakage), cervical cancer, and decreased fertility. Pregnant women have increased risk for spontaneous abortion, premature separation of the placenta from the uterine wall (a life-threatening complication for mother and fetus), placenta previa (in which the placenta implants much lower in the uterus than normal, which may lead to hemorrhage), bleeding during pregnancy, and premature rupture of the placental membranes (which can lead to infection). Infants born to women who smoke during pregnancy are at increased risk for low birth weight (18,600 cases annually), and other developmental problems. In men, smoking lowers testosterone levels, and appears to increase male infertility.

Numerous other health problems are caused by smoking such as poor circulation in the extremities due to constricted blood vessels. This not only leads to constantly cold hands and feet; it often requires amputation of the lower extremities. Smoking also deadens the taste buds and the receptors in the nasal epithelium, interfering with the senses of taste and smell, and may also contribute to periodontal disease.

References http://www.faqs.org/health/topics/72/Cigarette-smoking.htm

 

Do we really have to go on. How does keeping the status quo a better alternative. E-Cigarettes may not be perfect but for every consumer that switches we can reduce overall health costs and help insure other needy people.

You can see which side of the fence we sit. And below you can read other blogs and articles of responsible reasoning. But you need to be the judge for your self so if you google e-cigarette news you can find other articles from people who have a different opinion. PS most articles carry a post your comment area make sure you read the general publics opinion as well you may be surprised.

 

 

 
So what is the big deal over electronic cigarettes? Why would any public health organization or quit smoking group be against a product that doesn’t produce smoke? Why would the FDA be so determined to undermine the electronic cigarette’s current success by misleading the public with false conclusions from it’s testing?

It all started when smoking was found to kill people. Then, the pharmaceutical companies found there was money to be made by selling smokers nicotine in hopes to get them off of smoking. These companies were required to get approval from the FDA to market their quit smoking products. Approval means huge sums of money paid to the FDA.

Many public health organizations and quit smoking groups get at least some of their money from pharmaceutical companies. Whether this was the driving factor or it was their hope of less people dieing from smoking, these crusaders against smoking got motivated. Not only did they recommend smokers quit smoking (often by using a pharmaceutical product) they demonized smokers. They did a good job. There is little tolerance in America today for a smoker.

Enter the electronic cigarette. This simple little device threatens to turn the tables of years of hate speech. It is much harder to hate an action of someone else if that actions hurts only the user…..or nobody at all. Some still will, but the ads against e-smoking won’t have the same impact as those against tobacco smoking.

Left unchecked, the electronic cigarette could put a dent in the tobacco market, a dent in the pharmaceutical nicotine market, and give pause to those who feel hate towards smokers. It is obvious the pharmaceutical companies, the tobacco companies, the public health organizations, and the FDA would rather avoid some, if not all, of these outcomes.

This is about a habit and it’s social acceptance. Certain groups want to maintain the status quo. We want a practical alternative to the issue of smoking.

 


 

 

 Quitting, It’s About an Alternative with the Electronic Cigarette

 
The current litigation between two electronic cigarette suppliers and the FDA has everyone in a tailspin. It certainly did not help that the FDA openly misled the public into believing that the electronic cigarette is as (or more) dangerous than tobacco cigarettes. Many medical health professionals have weighed in on this noting the following:

* Dr. Elizabeth Whelan, president of the American Council on Science and Health, called the FDA statement “distorted, incomplete, and misleading. She also noted that “products of combustion cause cancers, cardiovascular disease and lung disease, and more.”

* Dr. Joel Nitzkin, MD, MPH, DPA, FACPM, Chair, Tobacco Control Task Force, American Association of Public Health Physicians stated that “We have every reason to believe the hazard posed by electronic cigarettes would be much loweigarettes), we would eventually reduce the US death toll from more than 400,000 a year to less than 4,000, maybe as low as 400.”

* Michael Siegel, a physician, researcher and professor at the Boston University School of Public Health noted that “What the FDA and anti-smoking groups are doing is committing medical malpractice on a massive scale: on a population basis. They are essentially condemning 100,000-plus consumers to a return to the most deadly known conindividuals have reported a tremendousInstead improvement in their health since switching to electronic cigarettes.”

Just for the record, all of the above public health officials are anti-smoking advocates.

The FDA and many anti-smoking groups are calling for the electronic cigarette to be pulled from the market on the basis that it is not a proven quit smoking device. The Electronic Cigarette Association (ECA) President Matt Salmon, former US Congressman from Arizona, noted in a letter to Congress that the ECA “acknowledges the health risks of cigarette smoking and advocates that smokers quit. But we also recognize the struggles that many have in quitting and who are looking for a more convenient and better alternative to tobacco cigarettes. While some of our customers have reported using our devices to help them quit smoking by slowing reducing the nicotine delivery in our products, it is important to note that our member companies do not market their e-cigarettes as smoking cessation products nor make any such claims.”

What is most important is the idea of claims. The FDA was formally named in 1930, and the “FDA’s modern regulatory functions began with the passage of the 1906 Pure Food and Drugs Act, a law a quarter-century in the making that prohibited interstate commerce in adulterated and misbranded food and drugs.” The original act had huge issues mainly that “False therapeutic claims for patent medicines were basically unregulated, as the manufacturer had only to show that he personally believed that his remedy worked to avoid prosecution, and standards for food purity and content were nonexistent.”

In 1938, after the 1937 Elixir Sulfanilamide Incident, where the SE Massengil Company created an elixir containing diethylene glycol as the base ingredient was given to children with strep which led to painful deaths, the Federal Food, Drug and Cosmetic Act was put into place. Following, came several examples of “incidents” and “near incidents” that lead for further revision of the Act.

But the question that lies at the heart of this debate is the electronic cigarette liquid really a “new drug” and is the electronic cigarette hardware really a “medical device”? According to the FDA’s definition of “new drug”, they state that the definition of a drug includes “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals” To put this into comparison with other products on the market that do not require FDA approval, let us look at dietary supplements.

Currently, the FDA does not regulate dietary supplements. Those products do not have to be FDA approved for safety, however, they can be recalled by the FDA if there are enough complaints. The only responsibility the manufacturer holds is that “Manufacturers must make sure that product label information is truthful and not misleading.”

Keeping this idea in mind that products can be on the market without FDA regulation, lets look at nicotine. Currently, there is nothing contained within the FDA website referring to nicotine. However, there is a plant out there that has many of the same effects as nicotine and that is lobelia inflata which IS specifically mentioned on the FDA website. The FDA notes in Sec. 310.544 Drug products containing active ingredients offered over-the-counter (OTC) for use as a smoking deterrent, that “Any OTC drug product that is labeled, represented, or promoted as a smoking deterrent is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing.” But what happens if these claims are not to be made and the product clearly states that this product has not been evaluated by the FDA?

Now, let’s review what the FDA considers a “medical device”. The term “device”… means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is–
(1) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them,
(2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
(3) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

For comparison purposes, we need to look at tobacco vaporizers. Tobacco vaporizers are currently not FDA regulated. Many of the vaporizers currently sold on the market today, carry the warning that the vaporizer is not approved for medical-therapeutic purposes. If the electronic cigarette is simply a vaporizer, which is it as it uses no combustion, and there are currently hundreds of other products on the market that vaporize tobacco to deliver nicotine into the body, and those are not classified as “medical devices”, then these smaller, more compact versions should fall into the same category as the larger versions, like the Volcano.

If the electronic cigarette liquid uses ingredients that are found in traditional tobacco cigarettes, all ingredients are FDA approved as generally safe for consumption, and the supplier placing the product on the market is not making any claims, then based on the above arguments, the electronic cigarette liquid is not a “new drug” and therefor does not need to be approved by the FDA. This would also lead to the conclusion that if the liquid itself is not a “new drug”, then the hardware itself is not a “medical delivery device”.

Instead stands firm that smokers should have the option to smoke something other than tobacco cigarettes. There should be regulations and those regulations should be put forth by a regulatory body who understands that tobacco harm reduction products have a place in the free market.

 

 

Matt Salmon, former Congressmen and current President of The Electronic Cigarette Association responds to the FDA’s announcement regarding electronic cigarettes:

 

 

 

 

 

Below is the summary of the Technical Review and Analysis of FDA Report: “Evaluation of e-cigarettes”.

The review of the now infamous FDA report on electronic cigarettes was done by:

Janci Chunn Lindsay, Ph.D.
Exponent Health Sciences
Toxicology and Mechanistic Biology Division
10850 Richmond Ave. Suite 175
Houston, TX 77042
July 30, 2009

It was done on behalf of NJoy, who was one of the companies the FDA targeted with their testing. It is important to note that NJoy is also one of the companies currently in litigation with the FDA. The summary is below, but you can download the entire review of the FDA’s report on e-cigarettes in pdf here.

SUMMARY:

* The report failed to present standard protocols for proper study design with regards to
the testing of the referenced control device, documenting the number of samples tested
either within or across tests, or presenting statistical analyses when quantifiable results
were obtained.
* The chemical content of similar nicotine-containing FDA-approved products was not
completely described with respect to the presence of tobacco-specific nitrosamines
(TSNAs) and other tobacco-associated impurities that have also been found in nicotine
replacement therapy (NRT) devices at similar, if not higher, levels.
* In the lots that were tested by the FDA, none of the key chemicals of concern in this
study such as TSNAs and tobacco-associated impurities were able to be quantifiably
measured in the liquid of NJOY’s cartridges because they were all below the limits of
quantification (LOQ).
* All of the tobacco-associated impurities found in the NJOY products were “present
but at less than the level of the Nicotrol® inhaler [manufacturer] specification”
according to the FDA report.
* There is no indication in the published scientific literature that cotinine or β-nicotyrine
are carcinogenic or have toxicity ratings of concern. These were the only tobacco-
associated impurities found in trace levels in the vapor phase of (some of) NJOY’s
products.
* The report does not reflect the actual dose of nicotine delivered to the user from the
“control” Nicotrol® inhaler device when used as recommended by the manufacturer
(6–16 cartridges/day or 24–64 mg of nicotine, 50 mcg/100 mL puff). By comparison,
NJOY devices delivered 46 mcg/100 mL in the highest-strength cartridge tested,
according to the FDA report.
* Data presented in the report does not adequately support the opinion that users of
NJOY products would actually be exposed to TSNAs and tobacco-specific impurities
in the vapor phase during normal device use; and if exposed, that those levels would be
a health concern as compared to other FDA-approved products.

 

The Legal Argument about why the Electronic Cigarette is not a Nicotine Replacement Therapy

 

 

As noted in a previous about how the new tobacco legislation effects the electronic cigarette, we noted that in order for a product to be a drug it must be “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals”. And in order to be a new drug….it must be a drug.

So I contacted the Centers for Disease Control and Prevention (CDC) and asked if smoking was considered a disease. At first they just sent me all the statistics about how many people smoking kills. Then they got mad I kept asking. Then I eventually received this response:

“When reviewing responses related to tobacco use that were provided by CDC-INFO, we noticed your question asking if smoking is considered a disease. As noted by CDC-INFO, smoking is a primary risk factor for many diseases. Addiction to drugs, is viewed as a brain disease by the
National Institute on Drug Abuse (NIDA). For information about nicotine addiction, please visit NIDA’s Web site at
http://www.drugabuse.gov/ResearchReports/Nicotine/Nicotine.html and
http://www.drugabuse.gov/Infofacts/understand.html

So, according to the CDC, smoking is not a disease, but rather it may put the user at risk of getting an actual disease. Apparently they believe that NIDA is correct and being addicted to nicotine is a disease. Thus, the electronic cigarette [e-liquid] as a new drug is one that is intended to diagnosis, cure, mitigate, treat, or prevent the addiction to nicotine. Curing nicotine addiction would involve not using nicotine anymore.

This is why Snus or dissolvables are not Nicotine Replacement Therapy (NRT) products. They are not marketed as a way to quit smoking (quit using nicotine). They are marketed to be used indefinitely, i.e. to continue using nicotine.

The nicotine patch or gum is meant to ween the user off of nicotine until they no longer use it….thus curing them. There IS a stop usage date on NRT products.

Selling a consumer an electronic cigarette as a quit smoking device would mean it necessary to instruct the consumer to eventually move to zero nicotine e-liquid and/or to ultimately quit vaping altogether.

For those who think that the mere fact that there is a zero nicotine e-liquid available means it treats nicotine addiction; please note that there is zero nicotine Snus and even a zero nicotine patch that is apparently not an NRT, but yet does claim to help users quit smoking (quit using nicotine). Of course no drug, means no “new drug”, which means it isn’t a NRT.

If there is no stop usage date, then how can an electronic cigarette cure nicotine addiction? And how can continuing the action that got the user addicted to nicotine in the first place help cure their addiction? If smoking / vaping / using an electronic cigarette with zero nicotine is the cure, then so is smoking a zero nicotine tobacco cigarette. Oddly enough, these nicotine free cigarettes do claim to help the user quit smoking, but still they are not an NRT.

So we have products that contain nicotine, have no stop usage date, and make no quit smoking claims that are not NRTs (dissolvables, Snus)
We have products that contain no nicotine or any drugs, that do make quit smoking claims and they are not NRTs (zero nicotine patch, nicotine free cigarettes)
We have products that contain nicotine (or other drugs), have a stop usage date, and claim to help users quit smoking. These are NRTs (gum, patch, pills)

Which of these is most suitable for the electronic cigarette? To be classified as a new drug under the classification of a NRT, the product must 1) contain a drug and 2) have a stop using nicotine date or imply one with the claim of quitting smoking. Also, the American Lung Association states, “To be most effective, nicotine replacement products should be used in conjunction with a behavior change program.” It is pretty obvious that electronic smoking is a continuation of the action of smoking, thus making it a rather ineffective NRT at best.

Most reputable e-cigarette suppliers don’t claim it helps anyone quit smoking and there is no proof that it does. I have yet to see any manufacturer or supplier recommending a stop usage date. It can come with nicotine or not.

So an e-cigarette that contains no nicotine (or any other drug) and makes no quit smoking claims should be labeled (and regulated) as an NRT? If so it would be the only product of it’s kind.

And with nicotine e-liquid and no stop usage date, we have a product that perpetuates nicotine addiction, not cures it. The upside? Nicotine kills very, very, very few people (if any) but inhaling burning tobacco kills hundreds of thousands.

 

 
BOSTON, July 27 — The FDA recently went public with misleading information about the safety of electronic cigarettes and the marketing of the devices, not only using its clout but recruiting other prominent organizations to demonize a product that has great public health benefit potential.

A group of prominent doctors and tobacco researchers, including Dr. Michael Siegel at the Boston University School of Public Health, Dr. Joel Nitzkin of the AAPHP Tobacco Control Task Force, and Dr. Brad Rodu, Endowed Chair, Tobacco Harm Reduction Research University of Louisville, challenge the FDA to provide the full quantitative data of the study upon which the

FDA has based its warning against electronic cigarettes. They are concerned that the FDA’s disingenuous targeting of electronic cigarettes through a biased presentation of the scientific data has had significant negative impact upon the public perception of electronic cigarettes, when the best available evidence suggests that these have shown that the devices offer great potential to reduce serious health issues among traditional tobacco smokers.

In a July 22 news release, the FDA cited the detectable presence of carcinogens and “toxic chemicals” in a “small sample” of electronic cigarette cartridges as reason for alarm, singling out nitrosamines as particularly toxic. What the FDA fails to inform the public is that detectable amounts of carcinogens are also present in nicotine replacement products such as NicoDerm CQ and Nicorette gum, both approved by the FDA, and nitrosamines that can be also found in food items such bacon and beer. This double standard and alarmist attitude has had the significant and unfortunate effect of inducing hysteria among the public, discouraging tobacco smokers from using a product which is thought to be a significantly safer alternative to traditional tobacco.

Regrettably, the FDA has used biased reporting of this small and inconclusive study, the complete results of which have not been made public, to secure the vocal support of groups such as the American Academy of Pediatrics Tobacco Consortium, the Institute for Global Health, and the American Lung Association in their attack on electronic cigarettes. These researchers argue that it is absurd to consider taking electronic cigarettes off the market when it is the conventional ones which have been shown to be killing people. Further, the electronic cigarette community calls for accurate and fair reporting relative to the findings and statements of prominent medical professionals in favor of this new and important technology and challenges the media to tell the other side of the story.

“The FDA’s laboratory findings actually indicate that electronic cigarettes are much, much safer than conventional cigarettes,” says Dr. Michael Siegel. “The traces of carcinogens present are also present in nicotine replacement products. The FDA and the anti-smoking groups have fallen into a huge analytical trap as they have failed to ask the appropriate question. The question they are asking is: ‘Are electronic cigarettes safe?’ That is not the right question. The right question is: ‘Are electronic cigarettes much safer than traditional ones?’”

Dr. Rodu states, “The FDA tested e-cigarettes for TSNAs using a questionable sampling regimen, and the methods that were so sensitive that the results may have no possible significance to users. The agency failed to report specific levels of these contaminants, and it has failed to conduct similar testing of nicotine medicines that have been sold in the U.S. for over 20 years. These are not the actions of an agency that is science-based and consumer-focused. These pseudo-scientific actions are clearly intended to form the justification for banning a category of products that are probably 99.9% safer than cigarettes.”

Dr. Joel Nitzkin speaking as individual states, “The newly adopted FDA/Tobacco legislation will give full FDA approval to currently marketed conventional cigarettes. The new law encourages cigarette companies to produce new “reduced exposure” cigarettes to be marketed as reduced exposure products, with no scientific evidence that such reductions in exposure will reduce risk of future tobacco related illness and death. In the context of these provisions of the newly adopted FDA/Tobacco bill — FDA should be encouraging, not maligning the manufacture and sale of electronic cigarettes, and working with manufacturers to assure the highest possible quality control.”

###

For more information and interviews, contact:

Michael Siegel, MD, MPH
Professor
Department of Community Health Sciences
Boston University School of Public Health
617-638-5167
Email: mbsiegel@bu.edu

Joel L. Nitzkin, MD, MPH, DPA
Chair AAPHP Tobacco Control Task Force
Phone: 504 899 7893 or 800 598 2561
Fax: 504 899 7557
jln-md@mindspring.com
www.aaphp.org

Brad Rodu
Professor of Medicine
Endowed Chair, Tobacco Harm Reduction Research
University of Louisville
Phone: 502-561-7273
Email: brad.rodu@louisville.edu
http://rodutobaccotruth.blogspot.com


 

When The Smoke Clears

 

AILWIRE.COM, August 28, 2009 ) BOSTON   Connecticut Attorney General Richard Blumenthal recently announced plans to seek a ban on the sale of electronic cigarettes in the state. This ill-advised decision follows a federal Food and Drug Administration report that put a scare into electronic cigarette users across the country, telling them that these battery-powered devices — which deliver nicotine without burning tobacco like conventional cigarettes — are dangerous because they contain carcinogens.

The agency also reported that of 18 cartridges tested, one contained diethylene glycol, an ingredient in antifreeze. The FDA threatened to remove electronic cigarettes from the market and to take enforcement action — including potential criml sanctions — against product distributors.

Backed by the finding that e-cigarettes contain carcinogens and diethylene glycol, a number of anti-smoking groups and several other states in addition to Connecticut have jumped on the bandwagon, considering or enacting legislation to remove these "harmful" devices from the market.

However, the FDA failed to mention in its press conference that the levels of tobacco-specific nitrosamines (the carcinogens) detected in electronic cigarettes were extremely low, below the level allowed in nicotine replacement products, such as nicotine patches, inhalers and gum. The agency is not threatening to take nicotine patches or gum off the market, although they too contain detectable levels of carcinogens.

The nicotine in electronic cigarettes and FDA-approved nicotine replacement products is derived from tobacco, which makes traces of some tobacco carcinogens essentially inevitable.

The level of the same tobacco-specific nitrosamines in conventional cigarettes is at least 300 to 1,400 times higher than what has been detected in electronic cigarette cartridges. In other words, you would have to smoke as many as 1,400 electronic cigarettes to be potentially exposed to the same amount of these carcinogens as smoking one conventional cigarette.

In fact, the FDA failed to perform the laboratory test of most importance: a comparison to cigarettes which contain 57 identified carcinogens, while e-cigarettes don't contain any carcinogens at higher than trace levels.

The bottom line is this: Conventional cigarettes have been thoroughly tested. They are known to contain at least 10,000 chemicals, including about 57 carcinogens. Electronic cigarettes deliver nicotine without these 10,000 chemicals and 57 carcinogens. It doesn't take a rocket toxicologist to figure out that electronic cigarettes are a much, much safer alternative to conventional ones.

Unfortunately, what the FDA and the anti-smoking groups are essentially telling smokers is that they would rather have them continue to smoke the most toxic cigarettes — the conventional ones — rather than switch to a product that is likely orders of magnitude safer.

The question the FDA and the anti-smoking groups are asking is: "Are electronic cigarettes safe?" That is not the right question. The right question is: "Are electronic cigarettes much safer than conventional ones?" The FDA and anti-smoking groups are comparing electronic cigarettes to a solution of spring-fresh Maine mountain stream water. What they need to compare electronic cigarettes to is a Marlboro cigarette. This doesn't mean that there aren't problems with e-cigarettes that need to be addressed. This doesn't mean e-cigarette manufacturers shouldn't be asked to make certain changes, such as instituting tighter quality control procedures and making sure the propylene glycol void of diethylene glycol. This doesn't mean that there shouldn't be restrictions on the sale of these devices to minors.

But it does mean that it is lunacy to ban the product, especially given that the very same FDA is now approving deadly Marlboros, Winstons, Kools, Newports, Camels
The FDA and anti-smoking groups are on the verge of losing sight of the actual objective of public health regulation: to improve the overall population's health. The combination of FDA approval of conventional cigarettes and FDA banning of the much safer electronic ones would be ludicrous, would have detrimental population health effects and would send exactly the wrong message to the public.

The real threat to our children's health is not electronic cigarettes. It's the real ones.

(This commentary originally appeared in the Hartford Courant.)

- - - - - - - - - -
Dr. Michael Siegel is associate chairman and a professor in the Department of Community Health Sciences at Boston University. He is a physician who completed his residency in Preventive Medicine at the UC Berkeley School of Public Health and trained in epidemiology for two years at the Centers for Disease Control and Prevention in Atlanta before coming to Boston. With more than 20 years of experience in tobacco control, primarily as a researcher, Dr. Siegel’s primary interest is in the area of tobacco control, focusing on secondhand smoke health effects, exposure, and policies, cigarette advertising and marketing practices and their effects on youths, and evaluation of tobacco control policies and their impact on youth and adult smoking behavior. His primary teaching is in the areas of mass communication, marketing, and public health advocacy. He is co-author of a book, entitled “Marketing Public Health: Strategies to Promote Social Change” and has been active in promoting smoke-free bar and restaurant policies throughout the country. Dr. Siegel has served as an expert witness in several major tobacco litigation cases.

His research and writing on tobacco issues can be read at
http://tobaccoanalysis.blogspot.com/
His profile can be seen at
http://sph.bu.edu/index.php?option=com_sphdir&id=239&Itemid=340&INDEX=677

 

 

 

Despite 98 Suicides and 188 Suicide Attempts, FDA Favors Chantix Over Electronic Cigarettes

Tobacco Control Expert Dr. Michael Siegel Calls for a Scientific, Not Ideological or Political Response to the Electronic Cigarette Issue

(EMAILWIRE., September 08, 2009 ) BOSTON – An article in this week's issue of the Journal of the American Medical Association (JAMA) reports that the Food and Drug Administration (FDA) has now acknowledged receiving 98 reports of suicides and 188 reports of suicide attempts that appear to be linked to use of Chantix, a prescription medication for smoking cessation. In addition, the FDA has received reports of patients taking the drug being involved in motor vehicle crashes.

At the same time, the FDA which has approved Chantix, seems focused on keeping electronic cigarettes, which have yet to be proven harmful, from the public.

A growing number of tobacco control experts and medical professionals are questioning the motives of the FDA. Dr. Michael Siegel, associate chairman and a professor in the Department of Community Health Sciences at the Boston University School of Public Health, wonders why the FDA is threatening to take electronic cigarettes off the market.

“If
Chantix has been studied and has been found to have likely caused 98 deaths and an additional 188 attempted suicides and it is allowed to remain on the market because smoking cessation is such an important goal, then what is the point of removing e-cigarettes from the market while studying its potential adverse effects? Suppose e-cigarettes were to be found to have caused 100 deaths. Would that warrant taking it off the market, since it - like Chantix - is helping people to quit smoking?” Dr. Siegel asks in a statement released by the Center for Public Accountability in Tobacco Control.

According to the JAMA article: "Although varenicline’s label had already indicated potential psychiatric risks, the agency has continued to receive reports of attempted and completed suicide in varenicline-treated patients, including some who had no history of psychiatric problems. An FDA analysis, released earlier this year, of varenicline adverse event reports submitted to the agency between May 2006 and November 2007 documented 19 suicides and 18 reports of suicidal behaviors, including 15 suicide attempts... But at a press briefing in July, Rosebraugh said that based on crude counts the agency now has reports of 98 suicides and 188 suicide attempts."
The JAMA article also notes that the FDA is requiring Pfizer, the makers of Chantix, to conduct clinical studies to determine the incidence and severity of the adverse effects of Chantix: "To better understand the incidence of these adverse events and which patients may be at greatest risk, the FDA is requiring the manufacturers of both drugs to conduct additional randomized controlled trials. Unlike previous studies, these trials will include individuals with preexisting mental health conditions, who make up a disproportionate number of smokers."

Siegel notes that unlike Chantix - for which there were many immediate post-marketing reports of potential adverse effects -- e-cigarettes have been on the market for more than three years and there have yet to be any severe adverse effects reported.

“In other words, we know that people are dying from taking Chantix but we're going to allow it to remain on the market because it's helping people to quit smoking. We know that there is no evidence that anyone is dying from using electronic cigarettes, but we're going to take them off the market, even though they are helping people to quit smoking. That just doesn't make any sense,” Dr. Siegel said.

Another thing that troubles Dr. Siegel is why anti-smoking groups are calling for the removal of e-cigarettes from the market, “when we are not aware of any documented severe adverse effects, yet they are not calling for the removal of Chantix from the market even though we know this drug is probably killing people.”

One answer, he believes, is the heavy financial influence of the pharmaceutical industry. “So far, every anti-smoking group which has called for the removal of e-cigarettes from the market has been found to be financially tied to Big Pharma. The Campaign for Tobacco-Free Kids, American Cancer Society, American Heart Association, American Lung Association, and Action on Smoking and Health have all received funding of some sort from the pharmaceutical industry. None of these groups, however, disclosed their financial conflicts of interest when they called for a ban on electronic cigarettes.”

On September 2, Pfizer was fined $2.3 billion by Federal prosecutors for illegal drug promotion. Authorities called Pfizer a repeat offender, citing this was the fourth such settlement in the past ten years.

Dr. Siegel is concerned that the one constituency not being represented here is the public, which would want a reasonable alternative to products that are known to cause harm.

“I believe that not only are the actions of these groups inappropriate, unsupported by science, harmful to the public's health, and heavily biased due to financial relationships, but these actions are also unethical because it is unscrupulous to advocate for a public policy like this without revealing such an important and relevant financial conflict of interest,” Dr. Siegel said.


Dr.
Michael Siegel is associate chairman and a professor in the Department of Community Health Sciences at Boston University. He is a physician who completed his residency in Preventive Medicine at the UC Berkeley School of Public Health and trained in epidemiology for two years at the Centers for Disease Control and Prevention in Atlanta before coming to Boston. With more than 20 years of experience in tobacco control, primarily as a researcher, Dr. Siegel’s primary interest is in the area of tobacco control, focusing on secondhand smoke health effects, exposure, and policies, cigarette advertising and marketing practices and their effects on youths, and evaluation of tobacco control policies and their impact on youth and adult smoking behavior. His primary teaching is in the areas of mass communication, marketing, and public health advocacy. He is co-author of a book, entitled “Marketing Public Health: Strategies to Promote Social Change” and has been active in promoting smoke-free bar and restaurant policies throughout the country. Dr. Siegel has served as an expert witness in several major tobacco litigation cases. His research and writing on tobacco issues can be read at http://tobaccoanalysis.blogspot.com/.
 
 

 
 
 

 

Get Linked from thousands of Classifieds for FREE with one click.

Bookmark and Share

 
 

                                       

HOME PAGE

MODEL 702 ELECTRONIC CIGARETTE

CONTACT US

REFERRAL PROGRAM

user comments

E-CIGARETTE MODEL 701

MODEL 84C E-CIGARETTE

 

 

Site map

MODEL 501 ELECTRONIC CIGARETTE

FAQ 

ELECTRONIC CIGARETTES

 

 

ELECTRONIC CIGARETTE

 ACCESSORIES

 

100% Satisfaction

OPERATION MANUAL

 &

TROUBLE SHOOTING

Model # 801 e-cigarette

      

Copywright 2009 Luck-e-Strike electronic cigarette, smokeless  cigarettes, Quit Smoking Products, LLC, - All Rights Reserved